Document Detail


Newer developments in therapy for endemic mycoses.
MedLine Citation:
PMID:  7948568     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In the 1960s and 1970s, amphotericin B was the only effective therapy for serious systemic endemic fungal infections due to Histoplasma capsulatum, Blastomyces dermatitidis, and Sporothrix schenckii. In the 1980s, ketoconazole was introduced as therapy for endemic mycoses; after this antifungal agent was introduced, some of these infections could be treated orally in an outpatient setting rather than intravenously in an inpatient setting. The 1990s have become the triazole era. It is now standard practice to treat nonmeningeal, non-life-threatening histoplasmosis and blastomycosis orally on an outpatient basis; the drug of choice for this treatment is itraconazole. Itraconazole also has proved useful as treatment for histoplasmosis in patients infected with human immunodeficiency virus. Although itraconazole has not yet been approved for the treatment of sporotrichosis, in preliminary studies it has been shown to be effective therapy not only for cutaneous and lymphocutaneous sporotrichosis but also for disseminated infection with S. schenckii.
Authors:
C A Kauffman
Related Documents :
9776808 - Characteristic infectivity of sporothrix schenckii to mice depending on routes of infec...
122648 - Treatment of fungal infections with miconazole.
12854088 - Experimental pulmonary aspergillosis due to aspergillus terreus: pathogenesis and treat...
11827268 - Assessing risk factors for systemic fungal infections.
2312218 - Seasonality of two gill monogeneans from two freshwater fish from an oligotrophic lake ...
2526408 - Characterization of brucella canis protein antigens and polypeptide antibody responses ...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America     Volume:  19 Suppl 1     ISSN:  1058-4838     ISO Abbreviation:  Clin. Infect. Dis.     Publication Date:  1994 Aug 
Date Detail:
Created Date:  1994-12-12     Completed Date:  1994-12-12     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  9203213     Medline TA:  Clin Infect Dis     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S28-32     Citation Subset:  IM; X    
Affiliation:
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antifungal Agents / therapeutic use*
Blastomycosis / drug therapy
Histoplasmosis / drug therapy
Humans
Itraconazole / therapeutic use
Mycoses / drug therapy*
Sporotrichosis / drug therapy
Grant Support
ID/Acronym/Agency:
DMID-91-04//PHS HHS
Chemical
Reg. No./Substance:
0/Antifungal Agents; 84625-61-6/Itraconazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Histoplasmosis: recognition and treatment.
Next Document:  Clinical aspects of fungal infection in organ transplant recipients.